4 Healthcare Stock Stories For a Weekend Investment Checkup

Epizyme, Inc. (NASDAQ:EPZM): Closing price $31.34

The firm said Friday that the FDA has granted orphan drug designation for EPZ-5676. Criteria for orphan drug designation mandates that the product be intended for treatment of a rare disease or condition, and classified as affecting fewer than 200,000 people in the United States. Epizyme is a clinical stage biopharmaceutical firm that creates innovative personalized therapeutics for patients having genetically defined cancers.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

EPZM-20130816

Health Management Associates, Inc. (NYSE: HMA): Closing price $12.97

Health Management announced Friday that a majority of its shareholders have named a new board of directors which comprises the eight nominees put forth by Glenview Capital Management. The new members of the board include Mary Taylor Behrens, Steven Epstein, Kirk Gorman, Joann Reed, Stephen Guillard, John McCarty, Steven Shulman and Peter Urbanowicz. Biographical information for these new board members will be provided in a Form 8-K to be filed by the firm with the Securities and Exchange Commission.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.
HMA-20130816

Stereotaxis, Inc. (NASDAQ:STXS): Closing price $4.16

On Friday, Stereotaxis announced that it has received a positive determination from the NASDAQ Listing Qualifications Panel on Thursday, granting approval of its request to transfer its listing to The NASDAQ Capital Market from The NASDAQ Global Market. The firm’s securities will commence trading on the NASDAQ Capital Market effective at the open on Monday. It is not anticipated that the transfer of Stereotaxis’ listing to The NASDAQ Capital Market should have any impact on trading in shares, which will continue to trade on NASDAQ under the symbol STXS.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

STXS-20130816

Cardica, Inc. (NASDAQ:CRDC): Closing price $1.30

Cardica said Friday that it filed regulatory documents with the FDA for marketing approval of the MicroCutter XCHANGE 30, which is a cutting and stapling device created to be employed in multiple open and minimally invasive surgical procedures. The XCHANGE 30 contains a cross-sectional area six times smaller than conventional surgical staplers, and articulates as far as 80 degrees in each direction. The lower profile allows for greater access through a 5 mm trocar.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CRDC-20130816

Don’t Miss: Education Officials: Schools Fear Obamacare Costs.